Anyone else dealing with cost-effectiveness analysis glp-1 agonists vs bariatric from a cost perspective?

I have been paying $280/month and I am trying to get insurance to cover it.

Share what you are paying and what you are getting — transparency helps everyone.

Good question. For Cost-effectiveness analysis GLP-1, here is what the evidence says:

• The clinical trial data (SURMOUNT program) supports this approach
• Real-world results from this community generally confirm the trial findings
• Individual variation is real — give it at least 8 weeks before judging

Happy to go deeper on any of these points if helpful.

Dr.KarenChen said:

For Cost-effectiveness analysis GLP-1, here is what the evidence says:The clinical trial data (SURMO

Completely agree with Dr.KarenChen. I would add that Cost-effectiveness analysis also has implications for long-term metabolic health that sometimes get overlooked in these discussions.

In my case, following a similar approach led to significant improvements compared to what I was doing before.

Exactly this. My pharmacist said the same thing about Cost-effectiveness.

As a pharmacist, I want to add some clinical context to this discussion on Cost-effectiveness analysis GLP-1.

Building on what SkepticalSean said — the evidence base here is robust. The key publications to reference are from the SUSTAIN program[1].

Key clinical points:

1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
2. Side effect profile is predictable and usually manageable with standard protocols
3. Monitoring should include baseline labs and follow-up at 3-month intervals
4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.